Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-severe Pain Following Abdominal Surgery

PHASE3CompletedINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

January 29, 2024

Primary Completion Date

November 20, 2024

Study Completion Date

February 10, 2025

Conditions
Participants With Acute Moderate to Severe Pain Following Abdominal Surgery
Interventions
DRUG

Meloxicam Injection

Intravenous meloxicam Injection, 30mg every 24 hours, for a total of 2 doses

DRUG

Sodium Chloride Injection

Intravenous Sodium Chloride Injection, 18mg every 24 hours, for a total of 2 doses

Trial Locations (18)

Unknown

Cangzhou People's Hospital, Cangzhou

The Third Xiangya Hospital Of Central South University, Changsha

Heping Hospital Affiliated To Changzhi Medical College, Changzhi

Sichuan Academy of Medical Sciengces & Sichuan Provincial People's Hospital, Chengdu

The Second People's Hospital Of Chengdu, Chengdu

The Third People's Hospital Of Chengdu, Chengdu

The First People's Hospital Of Guangyuan, Guangyuan

The First affiliated Hospital Of Jinan University, Guangzhou

The Affiliated Hospital Of Guizhou Medical University, Guizhou

Haikou People's Hospital, Haikou

The Second Hospital Of Anhui Medical University, Hefei

The First Affiliated Hospital Of University Of South ChinaThe First Affiliated Hospital Of University Of South China, Hengyang

Meihekou Central Hospital, Meihekou

Nanjing Women and Children's Healthcare Hospital, Nanjing

The Second Nanning People's Hospital, Nanning

Ningbo Medical Center Lihuili Hospital, Ningbo

The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou

The First Affiliated Hospital Of Xi'an Medical University, Xi'an

All Listed Sponsors
lead

Yangtze River Pharmaceutical Group Co., Ltd.

INDUSTRY

NCT06904248 - Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-severe Pain Following Abdominal Surgery | Biotech Hunter | Biotech Hunter